Novocure Reports First Quarter 2019 Financial Results and Provides Company Update

Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018

Mesothelioma humanitarian device exemption application under FDA review

Enrollment ongoing in four phase 3 pivotal trials, creating a significant market expansion opportunity in some of the most aggressive forms of cancer

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2019, highlighting continued revenue growth, an advancing clinical pipeline and a strong cash position. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields.

First quarter 2019 highlights include:

         

Three months ended
March 31,

2019     2018 % Change
 
Non-financial
Active patients at period end(1) 2,631 2,009

 

 

31

%
Prescriptions received in period(2) 1,310 1,258

 

 

4

%
 
Financial, in million
Net revenues $ 73.3 $ 52.1 41 %
Net loss $ (12.2 ) $ (20.7 ) -41 %
 
Cash and cash equivalents at the end of period $ 152.1 $ 111.6 36 %
Short-term investments at the end of period $ 104.5 $ 104.7

 

   
(1) An “active patient” is a patient who is on Optune under a commercial prescription order as of the measurement date, including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days.
 
(2) A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with Optune for a patient not previously on Optune. Orders to renew or extend treatment are not included in this total.
 

“With more than 2,600 patients on Optune as of March 31, 2019, we delivered another quarter of strong financial performance. We posted $73.3 million in net revenues in the first quarter 2019 with year-over-year revenue growth of 41 percent,” said Asaf Danziger, Novocure’s Chief Executive Officer. “We also strengthened our balance sheet, adding more than $10 million in cash, cash equivalents and short-term investments in the first quarter. We continued to fund our increased investments in clinical trials and Optune technology improvements with cash flow from the GBM business.”

“Our clinical pipeline continues to advance. Our HDE application for malignant pleural mesothelioma is under review at the FDA and, with the first patient enrolled in our INNOVATE-3 trial in March, enrollment is now ongoing in four phase 3 pivotal trials, creating a significant market expansion opportunity,” added William Doyle, Novocure’s Executive Chairman. “We believe we are at an important inflection point, transitioning to cash generation while expanding globally, driving clinical trials and investing in technology improvements as we work to extend survival in some of the most aggressive forms of cancer.”

First quarter 2019 operating statistics and financial update

There were 2,631 active patients on Optune at March 31, 2019, representing 31 percent growth versus March 31, 2018, and 10 percent growth versus December 31, 2018. The increase in active patients was driven primarily by prescription growth in EMEA and Japan and the ongoing benefit from continued growth in prescriptions for patients with newly diagnosed GBM globally.

  • In the United States, there were 1,778 active patients on Optune at March 31, 2019, representing 23 percent growth versus March 31, 2018.
  • In Germany and other EMEA markets, there were 735 active patients on Optune at March 31, 2019, representing 35 percent growth versus March 31, 2018.
  • In Japan, there were 118 active patients on Optune at March 31, 2019, representing 490 percent growth versus March 31, 2018.

Additionally, 1,310 prescriptions were received in the three months ended March 31, 2019, representing four percent growth compared to the same period in 2018, and flat versus the three months ended December 31, 2018.

  • In the United States, 925 prescriptions were received in the three months ended March 31, 2019, representing a two percent decline compared to the same period in 2018.
  • In Germany and other EMEA markets, 330 prescriptions were received in the three months ended March 31, 2019, representing 17 percent growth compared to the same period in 2018.
  • In Japan, 55 prescriptions were received in the three months ended March 31, 2019, representing 83 percent growth compared to the same period in 2018.

For the three months ended March 31, 2019, net revenues were $73.3 million, representing 41 percent growth versus the same period in 2018. Revenue growth was primarily driven by an increase of 622 active patients in our currently active markets, representing 31 percent growth, and an increase in net revenues per active patient. The increase in net revenues per active patient was primarily driven by improving reimbursement approval rates in Germany and by growth in Austria and Japan.

For the three months ended March 31, 2019, cost of revenues was $19.8 million compared to $18.2 million for the same period in 2018, representing an increase of 9 percent. The increase in cost of revenues was primarily due to the cost of shipping transducer arrays to a higher volume of active patients. Gross margin was 73% for the three months ended March 31, 2019 compared to 65% for the three months ended March 31, 2018.

Research, development and clinical trials expenses for the three months ended March 31, 2019, were $17.0 million compared to $11.1 million for the same period in 2018, representing an increase of 53 percent. This was primarily due to an increase in clinical trial and personnel expenses for our INNOVATE-3, LUNAR, METIS and PANOVA-3 trials and an increase in costs associated with medical affairs, regulatory and engineering.

Sales and marketing expenses for the three months ended March 31, 2019, were $22.3 million compared to $18.1 million for the same period in 2018, representing an increase of 23 percent. This was primarily due to increased marketing expenses and increased personnel costs associated with a larger sales force globally.

General and administrative expenses for the three months ended March 31, 2019, were $20.2 million compared to $17.3 million for the same period in 2018, representing an increase of 17 percent. This was primarily due to an increase in personnel costs and an increase in professional services.

Personnel costs for the three months ended March 31, 2019, included $9.7 million in non-cash share-based compensation expenses, comprised of $0.4 million in cost of revenues; $1.2 million in research, development and clinical trials; $2.0 million in sales and marketing; and $6.1 million in general and administrative expenses. Total non-cash share-based compensation expenses for the first quarter 2018 were $8.5 million.

Net loss for the three months ended March 31, 2019, was $12.2 million, or $0.13 per share, compared to net loss of $20.7 million for the same period in 2018, or $0.23 per share, representing an improvement of 41 percent.

At March 31, 2019, we had $152.1 million in cash and cash equivalents and $104.5 million in short-term investments, for a total balance of $256.6 million in cash, cash equivalents and short-term investments.

Anticipated clinical and regulatory milestones

  • FDA approval for unresectable malignant pleural mesothelioma (2019)
  • Zai Lab initiation of phase 2 pilot trial in gastric cancer (2019)
  • Data from phase 2 pilot HEPANOVA trial in advanced liver cancer (2020)
  • Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2020)
  • Data from phase 3 pivotal METIS trial in brain metastases (2021)
  • Interim analysis of phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2021)
  • Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021)
  • Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2022)
  • Final data from phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2022)
  • Final data from phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2024)

Conference call details

Novocure will host a conference call and webcast to discuss first quarter 2018 financial results today, Thursday, May 2, 2019, at 8 a.m. EDT. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 8956998.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 28, 2019, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

 

Consolidated Statements of Operations

USD in thousands (except share and per share data)

 
     

Three months ended March 31,

 

Year ended
December 31,

2019   2018 2018
Unaudited Audited
Net revenues $ 73,309 $ 52,125 $ 248,069
Cost of revenues   19,814   18,238   80,048
Gross profit   53,495   33,887   168,021
 
Operating costs and expenses:
Research, development and clinical trials 17,042 11,104 50,574
Sales and marketing 22,333 18,135 77,663
General and administrative   20,238   17,325   73,456
Total operating costs and expenses   59,613   46,564   201,693
 
Operating loss (6,118 ) (12,677 ) (33,672 )
Financial expenses, net   2,371   4,853   12,270
 
Loss before income taxes (8,489 ) (17,530 ) (45,942 )
Income taxes   3,661   3,194   17,617
Net loss $ (12,150 ) $ (20,724 ) $ (63,559 )
 
Basic and diluted net loss per ordinary share $ (0.13 ) $ (0.23 ) $ (0.69 )

Weighted average number of ordinary shares used in computing basic and diluted net loss per share

 

  94,811,282   89,985,612   91,828,043
 
 

Consolidated Balance Sheets

USD in thousands (except share data)

 
      March 31,     December 31,
2019 2018
Unaudited Audited
ASSETS
 
CURRENT ASSETS:
Cash and cash equivalents $ 152,067 $ 140,622
Short-term investments 104,535 105,256
Restricted cash 2,094 2,134
Trade receivables 39,220 36,523
Receivables and prepaid expenses 13,619 14,279
Inventories   24,138   22,555
Total current assets   335,673   321,369
 
LONG-TERM ASSETS:
Property and equipment, net 8,421 8,442
Field equipment, net 7,266 6,924
Right-of-use assets, net 13,920
Other long-term assets   4,975   3,058
Total long-term assets   34,582   18,424
 
TOTAL ASSETS $ 370,255 $ 339,793
 
 

Consolidated Balance Sheets

USD in thousands (except share data)

 
  March 31,     December 31,
2019 2018
Unaudited Audited
LIABILITIES AND SHAREHOLDERS’ EQUITY
 
CURRENT LIABILITIES:
Trade payables $ 29,943 $ 26,708
Other payables, lease liabilities and accrued expenses   41,005   37,852
Total current liabilities   70,948   64,560
 
LONG-TERM LIABILITIES:
Long-term loan, net of discount and issuance costs 149,305 149,268
Deferred revenue 9,407 9,929
Employee benefit liabilities 2,823 2,683
Long-term lease liabilities 11,015
Other long-term liabilities   363   1,094
Total long-term liabilities   172,913   162,974
 
TOTAL LIABILITIES   243,861   227,534
 
COMMITMENTS AND CONTINGENCIES
 
SHAREHOLDERS’ EQUITY:
Share capital –

Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 95,692,797 shares and 93,254,185 shares at March 31, 2019 (unaudited) and December 31, 2018, respectively

Additional paid-in capital 783,941 757,314
Accumulated other comprehensive loss (1,742 ) (1,400 )
Accumulated deficit   (655,805 )   (643,655 )
Total shareholders’ equity   126,394   112,259
 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 370,255 $ 339,793
 

Media and Investor Contact:
Ashley Cordova
acordova@novocure.com
212-767-7558

Source: Novocure

Print Friendly, PDF & Email